14 research outputs found
Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women
Change in serum concentrations of BAP from baseline to week 24 in the evaluable population
<p><b>Copyright information:</b></p><p>Taken from "Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women"</p><p>http://breast-cancer-research.com/content/9/4/R52</p><p>Breast cancer research : BCR 2007;9(4):R52-R52.</p><p>Published online 10 Aug 2007</p><p>PMCID:PMC2206728.</p><p></p> BAP, bone alkaline phosphatase
Change in serum concentrations of PINP from baseline to week 24 in the evaluable population
<p><b>Copyright information:</b></p><p>Taken from "Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women"</p><p>http://breast-cancer-research.com/content/9/4/R52</p><p>Breast cancer research : BCR 2007;9(4):R52-R52.</p><p>Published online 10 Aug 2007</p><p>PMCID:PMC2206728.</p><p></p> The median percentage change (95% CI) from baseline was consistently positive only for exemestane (24%; 95% CI, 11–30%). The overall differences between the four groups were not statistically significant (= 0.147 using the Kruskall–Wallis test). CI, confidence interval; PINP, procollagen type I N-terminal propeptide
Change in U-NTx concentrations from baseline to week 24 in the evaluable population
<p><b>Copyright information:</b></p><p>Taken from "Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women"</p><p>http://breast-cancer-research.com/content/9/4/R52</p><p>Breast cancer research : BCR 2007;9(4):R52-R52.</p><p>Published online 10 Aug 2007</p><p>PMCID:PMC2206728.</p><p></p> UNTx, adjusted urinary N-terminal telopeptide of type I collagen
Baseline-adjusted AUCfor serum concentrations of PINP in the evaluable population
<p><b>Copyright information:</b></p><p>Taken from "Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women"</p><p>http://breast-cancer-research.com/content/9/4/R52</p><p>Breast cancer research : BCR 2007;9(4):R52-R52.</p><p>Published online 10 Aug 2007</p><p>PMCID:PMC2206728.</p><p></p> The increase in baseline-adjusted AUCfor exemestane was 187% (95% CI, 95–295%). The AUCfor exemestane was significantly greater than anastrozole (= 0.004), letrozole (< 0.001), or placebo (= 0.033). Changes in baseline-adjusted AUCwere not statistically significant for other active treatments or placebo. The overall differences between the four groups were statistically significant (= 0.004 using the Kruskall–Wallis test). AUC, area under the curve; PINP, procollagen type I N-terminal propeptide
Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios
With high survival rates for chronic myeloid leukemia (CML) patients treated with BCR-ABL1 tyrosine kinase inhibitors (TKIs), emerging consequences, such as arterial ischemic events, require consideration when evaluating treatment options. Cardiovascular ischemic event incidence in clinical trials was evaluated in 2712 dasatinib-treated patients with Philadelphia chromosome-positive (Ph+) leukemias from 11 first- and second-line trials (pooled), newly diagnosed CML patients treated with dasatinib or imatinib (DASISION), and prostate cancer patients treated with dasatinib or placebo plus docetaxel/prednisone (READY). Overall, 2-4% of dasatinib-treated patients had cardiovascular ischemic events. Most dasatinib-treated patients with an event had a history of and/or risk factor for atherosclerosis (pooled 77 with history/risk and event/96 with events; DASISION 8/10; READY 15/18). Most cardiovascular ischemic events occurred within 1 year of initiating dasatinib (pooled 69/96; DASISION 7/10; READY 16/18). Comparison of observed and expected event rates through standardized incidence ratios indicates that dasatinib does not increase risk for cardiovascular ischemic events compared with external reference populations